RheothRx Injection data

The Norcross, Ga., company presented Phase II data from 144 patients at the American College of Cardiology meeting, showing that the surfactant given as an adjunct to clot dissolvers decreased infarct size by 38 percent (p = 0.017).

Of the 75 patients who received the surfactant as a 48-hour, continuous infusion after either streptokinase or tPA, one had a repeat heart attack while in the hospital, compared to five patients out of 39 who got a thrombolytic and a placebo infusion (p = 0.016). ...